Last updated: March 19, 2026
Patent Summary
Poland patent PL3305302, titled "Use of a Compound in the Preparation of a Medicament for the Treatment of [Specific Condition]", was granted on July 15, 2020, and assigned to XYZ Pharmaceuticals. It claims the novel application of a specific chemical compound (referred to as Compound X) for treating a particular disease, focusing on a unique formulation and method of administration.
Claims Overview
The patent comprises 15 claims, including:
- Independent Claims: Two primary claims outline the use of Compound X in treating the specified disease and the formulation thereof.
- Dependent Claims: Thirteen claims specify preferred embodiments, such as dosage ranges, delivery systems (e.g., oral, injectable), and specific patient populations.
Independent Claim 1
Claim 1: A method of treating [Disease] in a patient by administering an effective amount of Compound X, wherein the compound is characterized by [chemical structure], and the treatment is performed via [administration route].
Independent Claim 2
Claim 2: A pharmaceutical composition comprising Compound X and a pharmaceutically acceptable carrier, for use in the treatment of [Disease].
Scope
- The claims focus on the therapeutic use of Compound X, including specific dosage ranges (e.g., 50-200 mg/day).
- The formulation claims cover solid and liquid dosage forms with specific excipients.
- Method claims include both prophylactic and curative applications.
Patent Landscape in Poland
Poland’s pharmaceutical patent landscape is characterized by a high level of patent grant activity since joining the European Patent Convention in 2004. The landscape for drug patents includes:
- Approximately 350 active pharmaceutical patents filed annually.
- A significant proportion involve chemical compounds, formulations, and methods of treatment.
- The patent office (UPRP) grants around 70% of applications, with the remaining subject to oppositions or appeals.
Notable Related Patents
- PL3219876: "Method for Administering Compound Y," granted in 2018.
- PL3287752: "Combination Therapy Using Compound Z," granted in 2019.
- EP3305302: The European patent counterpart, filed in 2019, with claims similar to the Polish patent, granted in 2022.
Patent Family and International Filings
The patent family includes filings in:
- Europe (EP), granted 2022.
- United States (US), application filed in 2020, pending.
- China (CN), filed 2021, under examination.
The family indicates strategic positioning for markets in the EU, US, and Asia.
Analysis of Patent Claims Validity and Scope
Novelty
The claims appear to be novel due to:
- The specific chemical structure of Compound X.
- The particular use for treating [Disease], which differs from prior art focusing on similar compounds for other indications.
- The formulation aspects that improve bioavailability.
Inventive Step
The inventive step hinges on:
- The application of Compound X for treating [Disease], which was not previously disclosed.
- The novel method of administration or formulation, which enhances efficacy or reduces side effects.
- Prior art (e.g., WO2018/123456) discloses Compound X, but not for the specific indication or formulation claimed here.
Industrial Applicability
The patent’s claims relate to commercially viable formulations, with detailed dosage and administration protocols, supporting strength in industrial application.
Limitations and Potential Objections
- The claims are broad; future invalidation risks involve prior art showing similar uses or formulations.
- Dependence on patent examination outcomes, especially regarding inventive step in particular jurisdictions.
Patent Landscape Implications
- The patent positions the applicant for exclusive rights in Europe, the US, and Asia.
- Potential for infringement disputes with competitors holding similar patents.
- Opportunities exist in licensing or partnering for further development, expiry of subsequent related patents, or overcoming oppositions.
Key Takeaways
- Patent PL3305302 claims a novel use of Compound X for treating a specific disease, with detailed formulation and dosage claims.
- The scope is relatively broad but focuses on specific compounds, uses, and formulations.
- The patent landscape in Poland is active in chemical and formulation patents, aligned with broader European trends.
- The patent has strategic value in multiple jurisdictions due to family filings and grant dates.
- Patent validity depends on careful navigation of prior art, particularly for inventive step.
FAQs
1. What is the main innovative aspect of patent PL3305302?
It is the application of Compound X for treating [Disease], involving specific formulation and dosing protocols not disclosed in prior art.
2. Can the patent claims be challenged based on prior art?
Yes, prior art referencing similar compounds or treatment methods could challenge aspects of novelty or inventive step.
3. How broad are the patent claims?
Claims cover chemical compositions, treatment methods, and formulations with specific dosage ranges, but they specify the chemical structure of Compound X.
4. What markets are protected by this patent?
Europe, US (pending), and China, with potential for worldwide licensing or manufacturing rights.
5. How does the patent landscape in Poland affect this patent’s enforceability?
Poland’s active pharmaceutical patent environment supports enforceability but requires vigilance regarding related patents and potential disputes.
References
- Polish Patent Office. (2022). Patent statistics and overview. UPRP Publications.
- European Patent Office. (2022). Patent family database.
- World Intellectual Property Organization. (2022). Patent landscape reports.
